HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Digital Citizens Study Finds Many CBD Products Are Placebos And Most Are Inaccurately Labeled

Executive Summary

Digital Citizens Alliance found an average 30% discrepancy between labeled and actual CBD amounts in nearly 60 products. The group says more than half the products tested contained CBD levels 20% higher or lower than labeled, which is particularly problematic since nearly half US consumers use the products as alternatives to Rx drugs.

You may also be interested in...



HBW Market News: Baze Patents ‘Recommendation Engine,' Built Brands Revamps, Expands Capacity

Leafreport found 54% of 22 beverages contained less CBD than labeled; Built Brands rebrands protein, energy lineup with bigger facility to boost production; Baze Labs’ personalized nutrition “recommendation engine” patented; TruTrace blockchain platform for sanitizer; and Coffeeberry extract GRAS cleared by FDA.

False COVID-19 Claims In US Consumer Health Market: Rampant With Forecast For More

In addition to 45 businesses with varying levels of communication skills the FTC targeted in its latest batch of warnings about false advertising linked coronavirus, the FDA "sent hundreds of abuse complaints to domain name registrars and internet marketplaces" also linked to bogus COVID-19 claims.

US FDA Reopens Door For CBD Safety Data, But NPA Says Window Closing For Setting Safe Level

As it recently told Congress it would, FDA reopens docket on “Scientific Data and Information about Products Containing Cannabis or Cannabis-Derived,. "Reopening the comment period will do nothing to protect public health when the FDA is already sitting on a ticking time bomb," says NPA head Daniel Fabricant.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134044

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel